Wellington Management Group LLP Buys New Stake in Savara Inc (NASDAQ:SVRA)

Wellington Management Group LLP purchased a new position in Savara Inc (NASDAQ:SVRA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,060,173 shares of the company’s stock, valued at approximately $9,683,000. Wellington Management Group LLP owned about 1.52% of Savara at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SVRA. AJOVista LLC acquired a new position in Savara during the 4th quarter valued at approximately $40,000. SG Americas Securities LLC raised its stake in Savara by 34.2% in the 4th quarter. SG Americas Securities LLC now owns 49,862 shares of the company’s stock worth $234,000 after acquiring an additional 12,720 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Savara during the 4th quarter worth about $74,000. Tower Research Capital LLC TRC grew its stake in Savara by 665.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after purchasing an additional 16,959 shares during the last quarter. Finally, Algert Global LLC increased its holdings in shares of Savara by 128.3% in the third quarter. Algert Global LLC now owns 36,640 shares of the company’s stock valued at $138,000 after purchasing an additional 20,590 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Performance

Shares of SVRA stock opened at $3.81 on Friday. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22. Savara Inc has a 12-month low of $2.63 and a 12-month high of $5.70. The business’s 50 day moving average is $4.32 and its two-hundred day moving average is $4.63. The company has a market capitalization of $526.50 million, a P/E ratio of -10.30 and a beta of 0.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Analysts expect that Savara Inc will post -0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SVRA has been the topic of several research reports. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price target on shares of Savara in a report on Monday, May 6th. Guggenheim boosted their target price on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday. Piper Sandler increased their price target on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Oppenheimer boosted their price objective on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, HC Wainwright raised their target price on Savara from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $11.00.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.